Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jul 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether patients with liver cancer (called hepatocellular carcinoma or HCC) who respond partly to a combination medicine (atezolizumab and bevacizumab) and then receive additional treatments aimed at curing the cancer have better outcomes than those who respond to the medicine alone. Some patients see their tumors shrink enough after this medicine to have surgery or other treatments to try to remove or destroy the cancer completely. The study wants to find out if these extra “curative” treatments help patients live longer without the cancer coming back compared to those who don’t have these treatments.

Patients who have been diagnosed with HCC and have already received atezolizumab plus bevacizumab as their first treatment may be eligible, especially if their cancer has either partially or completely responded to this therapy. The study will look at information from medical records of patients worldwide to compare how long patients stay cancer-free after different treatment approaches. Participants won’t receive new treatments as part of this study since it reviews past medical records, but their experiences will help doctors understand the best way to manage liver cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically or clinically (the presence of liver cirrhosis and typical HCC imaging findings by multi-phase CT or MRI) diagnosed HCC.
• • 2. Received Atezo-Bev containing treatment as first-line systemic therapy for HCC
• • 3. Patients with or without macrovascular invasion and main portal vein invasion before Atezo-Bev containing treatment can be enrolled
• • 4. Patients with or without extrahepatic spread before Atezo-Bev containing treatment can be enrolled
• • 5. Obtained CR or PR, according to RECIST version 1.1, to Atezo-Bev treatment
• Exclusion Criteria:
• • 1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
• • 2. Received anti-CTLA4 antibodies simultaneously with Atezo-Bev Patients who received Atezo-Bev in combination with investigational drugs such as tiragolumab, relatlimab, and tocilizumab were allowed to enter the study.
• • 3. Received locoregional therapy simultaneously with Atezo-Bev treatment, such as transarterial chemoembolization (TACE), hepatic arterial infusion of chemotherapy (HAIC), transarterial radioembolization, radiofrequency ablation, and microwave ablation before obtaining PR or not for curative intent